NCRI Press Release, 9 November 2016
Date published: Apr 03 2018
Marker for aggressive prostate cancer doubles-up as a drug target
Download the attachmentRecent Tweets
-
Take a look at this #TwitterMoment and find out about the #ChildhoodCancer research conducted by some of NCRI's par… https://t.co/ajJepLdIkd
10 hours ago -
Have you registered for the next #NCRIVirtual webinar? Join us on tomorrow for 'Screening and early detection of ca… https://t.co/dAN0U0DwSD
15 hours ago -
Have you registered for the next #NCRIVirtual session? On Thursday expert speakers will discuss the potential value… https://t.co/wbiwDBJ0dI
18 hours ago
- 19 Mar 2020Workstream leads: NCRI Skin Group
- 26 Nov 2019CM-Path - Application for Consumer Membership (Deadline - 1st January 2020)
- 20 Nov 2019With its new chair, Professor David Harrison, at the helm, CM-Path share top priorities
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed